DOPTELET® OneSource for Healthcare Professionals

 

ACCESS DOPTELET® (avatrombopag): DOVA 1SOURCE

A range of healthcare navigation support and financial assistance to help your patients

Dova® 1Source™

 

Dova 1Source can help your prescribed patients navigate access at any point through the fulfillment process.

 

Dedicated Care Coordinators can help:

 

Research your patient’s individual coverage for DOPTELET

 

Coordinate with an eligible specialty pharmacy to fill your patient’s prescription

 

Connect your patients with affordability options if needed. Patients must meet eligibility criteria

 

For more information and to access enrollment forms:

Or

Please call 1-833-DOVA-ONE (1-833-368-2663)

Care Coordinators are available Monday–Friday 8 AM–8 PM EST

About DOPTELET® (avatrombopag)

Learn how DOPTELET works with the body to increase platelet counts.1

Reference:

1. DOPTELET [package insert]. Durham, NC: Dova Pharmaceuticals, Inc.

INDICATION

DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.

IMPORTANT SAFETY INFORMATION FOR DOPTELET

Warnings and Precautions

DOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic liver disease. Portal vein thrombosis has been reported in patients with chronic liver disease treated with TPO receptor agonists. In the ADAPT-1 and ADAPT-2 clinical trials, there was 1 treatment-emergent event of portal vein thrombosis in a patient (n=1/430) with chronic liver disease and thrombocytopenia treated with DOPTELET. Consider the potential increased thrombotic risk when administering DOPTELET to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions (Factor V Leiden, Prothrombin 20210A, Antithrombin deficiency or Protein C or S deficiency).

DOPTELET should not be administered to patients with chronic liver disease in an attempt to normalize platelet counts.

Contraindications: None

Adverse Reactions

The most common adverse reactions (≥3%) were: pyrexia, abdominal pain, nausea, headache, fatigue, and edema peripheral.

 

Please see Full Prescribing Information for DOPTELET® (avatrombopag).

Visit Dova.com for WAC pricing.

 
 

INDICATION

DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.

IMPORTANT SAFETY INFORMATION FOR DOPTELET

Warnings and Precautions

DOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic liver disease. Portal vein thrombosis has been reported in patients with chronic liver disease treated with TPO receptor agonists. In the ADAPT-1 and ADAPT-2 clinical trials, there was 1 treatment-emergent event of portal vein thrombosis in a patient (n=1/430) with chronic liver disease and thrombocytopenia treated with DOPTELET. Consider the potential increased thrombotic risk when administering DOPTELET to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions (Factor V Leiden, Prothrombin 20210A, Antithrombin deficiency or Protein C or S deficiency).